231 results
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
cancers. Portage’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of clinical … , LLC (“Lincoln”), will be sufficient to meet its anticipated cash requirements through the end of September 2024. Access to the Committed Purchase
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
of life in patients with invasive cancers. Portage’s access to next-generation technologies coupled with a deep understanding of biological mechanisms … . Access to the Committed Purchase Agreement with Lincoln is generally limited based on, among other things, the Company’s Nasdaq trading volume
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with invasive cancers.
Our access … Offering, and will be exercisable for five years from the commencement of the sales pursuant to the Offerings.
Access to the Committed Purchase Agreement
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
access to next-generation technologies coupled with a deep understanding of biological mechanisms enable the identification of clinical therapies … . Access to the Committed Purchase Agreement with Lincoln, is generally limited based on, among other things, the Company’s Nasdaq trading volume
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Nov 23
Current report (foreign)
4:01pm
-term treatment response and quality of life in patients with invasive cancers. Portage’s access to next-generation technologies coupled with a deep … ”), will be sufficient to meet its anticipated cash requirements through the end of March 2024. Access to the Committed Purchase Agreement with Lincoln
6-K
EX-99.2
k93bkdfcc4h2b gkclhh
28 Nov 23
Current report (foreign)
4:01pm
424B3
c91o9qragmp9
7 Nov 23
Prospectus supplement
4:50pm
F-1
zcyvw1i1cg5yj2je 21h
31 Oct 23
Registration statement (foreign)
4:05pm
6-K
EX-10.1
lfw1hzzsp 8axk8i7huh
3 Oct 23
Current report (foreign)
4:05pm
424B5
60h6he2 rx612g9
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.2
tlnnz
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
c6yvbdn
29 Aug 23
Current report (foreign)
4:01pm